Neil Herbert – Executive Chairman – Atlantic Lithium (ASX:A11) is an AIM, ASX, GSE and OTCQX-listed lithium company advancing its flagship project, the Ewoyaa Lithium Project, a significant lithium spodumene pegmatite discovery in Ghana, through to production to become the country’s first lithium-producing mine.
Copyright 2024 – Finance News Network
11 Dec 2020 - Novatti Group Limited (ASX:NOV) Managing Director Peter Cook discusses the company's strategy of partnering with Tier 1 companies, including Ripple, Google Pay and Samsung Pay.
28 May 2021 - Beston Global Foods Limited (ASX:BFC) CFO and Acting CEO Darren Flew discusses the company's FY21 results, guidance and strategy, and provides an update on the company's lactoferrin expansion project at its Jervois dairy in South Australia.
27 Jun 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company's lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.
23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
20 Mar 2023 - Magontec Limited (ASX:MGL) Executive Chairman and CEO Nicholas Andrews discusses the magnesium industry, drivers of demand, China, supply chains into the US and Europe, and recent financial results.
20 Sep 2024 - Prime Financial Group Limited (ASX:PFG) Managing Director, CEO and Chairman Simon Madder provides an update on the company, discussing drivers behind FY24 performance, the acquisitions of Altor Capital and Equity Plan Management, and outlook.
19 May 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a surge in trading volume.
30 Sep 2020 - Mainstream Group Holdings Limited (ASX:MAI) CEO Martin Smith provides an update on the company's FY20 results, the impact of COVID-19, strategy and outlook.
08 Jan 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker, talks about the company’s plans to develop Anagrelide, for the treatment of cancer, and to commercialise its lead product ZolpiMist worldwide.
